Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapyYoshio Nakamura, Naoya Yamazaki, Shigehisa Kitano et al.|Oncotarget|2016Cited by 160
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patientsYasuhiro Nakamura, N. Yamazaki, Kenjiro Namikawa et al.|Annals of Oncology|2020Cited by 140
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanomaYasuhiro Fujisawa, Norito Katoh, Akane Minagawa et al.|Cancer Medicine|2019Cited by 111
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)Yasuhiro Nakamura, Naoya Yamazaki, Kenjiro Namikawa et al.|ESMO Open|2021Cited by 57
A review of the AJCC melanoma staging system in the TNM classification (eighth edition)Dai Ogata, Naoya Yamazaki, Kenjiro Namikawa et al.|Japanese Journal of Clinical Oncology|2021Cited by 40